Literature DB >> 8867109

Blocking effects of otilonium on Ca2+ channels and secretion in rat chromaffin cells.

L Gandía1, M G López, M Villarroya, J A Gilabert, A Cárdenas, A G García, R Borges.   

Abstract

We describe here the effects of otilonium bromide (an anticholinergic agent widely used as an intestinal spasmolytic) on whole-cell currents through Ca2+ channels (IBa) and catecholamine secretion in rat adrenal glands and isolated rat chromaffin cells. Otilonium blocked the peak IBa current in voltage-clamped chromaffin cells in a concentration-dependent manner; the IC50 to block IBa was 4.7 microM. Blockade was not accompanied by a significant shift in the I-V relationship for IBa, suggesting that such blockade was not affecting a specific subtype of Ca2+ channel. When given intracellularly through the patch pipette, otilonium (10 microM) did not block IBa. However, its external application to the same cell (10 microM) reversibly reduced IBa by 70%. Otilonium caused a concentration-dependent blockade of catecholamine release from perfused rat adrenal glands intermittently stimulated with methacholine, high K+ or histamine. The IC50 to block secretion after a 5 min incubation with otilonium was 0.02, 0.7 and 3 microM, respectively, for methacholine, K+ and histamine. The blocking effects of otilonium were fully reversible at concentrations below 10 microM. The Ca2+ channel agonist Bay K 8644 (methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyr idine-5- carboxylate) partially antagonized the effects of otilonium on K(+)-evoked secretion and accelerated the time course of recovery from inhibition. The results are compatible with the idea that otilonium blocks Ca2+ entry into chromaffin cells by blocking voltage-dependent Ca2+ channels. This would lead to a limitation in the rise in cytosolic Ca2+ at secretory sites and to inhibition of catecholamine release in response to stimulation of chromaffin cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867109     DOI: 10.1016/0014-2999(95)00808-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Authors:  Susanne Lindqvist; James Hernon; Paul Sharp; Neil Johns; Sarah Addison; Mark Watson; Richard Tighe; Shaun Greer; Jean Mackay; Michael Rhodes; Michael Lewis; William Stebbings; Chris Speakman; Stefano Evangelista; Ian Johnson; Mark Williams
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 3.  Inflammatory Signaling in Hypertension: Regulation of Adrenal Catecholamine Biosynthesis.

Authors:  Collin J Byrne; Sandhya Khurana; Aseem Kumar; T C Tai
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-28       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.